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What is A Substance Use Disorder? 
 
The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) recently changed how 
substance use disorders are defined and diagnosed. A substance use disorder is measured based on four 
behavioral categories, impaired control, risky use, social impairment, pharmacological indictors 
(tolerance and withdrawal) and is measured from mild to severe impairment (Kahan & Watt, 2017). 
The difference between a substance use disorder and substance abuse problem is dependent on the 
length of substance use. Long-term substance abuse problems are referred to as substance use 
disorders and should be treated as serious mental illnesses (SAMHSA, 2017). It is observed that 
persons with substance use disorders can live relatively normal lives and function adequately 
enough to survive day to day. Addiction and dependence are components of a substance use 
disorder. Addiction is when pursuit or, use of the substance begin to define the user’s life. Addictive 
behaviors are the symptom of psychological disorders in combination with chemical dependence. 
 
Introduction 
 
Substance use is a complex public health issue that needs to be addressed through multiple 
frameworks, and viewpoints. The cost of substance use on American productivity is estimated by the 
National Institute on Drug Abuse (NIDA) to be $740 billion annually (NIDA, 2017). The nationwide 
opioid epidemic has brought unprecedented attention to the public health issue of substance abuse. 
The spotlight is currently on opioids, but it is important to keep other prominent illicit substances in 
mind. The etiology of substance use is a complex issue that researchers are still trying to elucidate. 
Two variables that have been found to have a high association with the development of a substance 
use disorder are childhood trauma, and stress. These events are categorized as, adverse childhood 
events (ACEs). ACEs are strong predictors of the lifetime risk of substance use and engagement in 
risky behaviors (Dube et al., 2003). Substance use is also a known risk factor for engagement in risky 
sexual behaviors. This resource guide will discuss the lifetime epidemiological risk of substance use. 
This includes how substance use impacts a person’s risk of engagement in risky sexual behavior.  
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Alcohol 
Alcohol abuse is a pressing public health burden. The Centers for Disease Control and 
Prevention estimate that alcohol kills over 80,000 people per year and cost the United States $249 
billion in lost productivity in 2010 (CDC, 2018). Despite these statistics alcohol remains a staple of 
American culture. Public health officials need to fight not only the addictive power of alcohol, but also 
the power of alcohol advertising and cultural normalization. Social expectancies are an extremely 
important tool in understanding how alcohol impacts the health of a user.  
Research by George and Stoner (2000) describe how social expectancies shape the intentions of 
users. They found that sexual behavior is greatly influenced by alcohol consumption among men and 
women. Men and women perceive each other as more sexually attractive and sexually open when 
consuming alcohol. Men also reported associating alcohol with sexual behaviors, which increase their 
engagement in risky sexual behaviors. Based on large epidemiological surveys, such as the National 
Epidemiologic Survey on Alcohol and Related Conditions, men aged 18-25 have the highest risk of 
alcohol use disorder (AUD) (Delker, Brown, & Hasin, 2016).  
The risk among men differs between racial groups as well; white males having the highest 
prevalence of alcohol consumption, especially older white men. Despite the high prevalence of alcohol 
consumption among white males, the highest prevalence of AUD is among Native Americans (Delker et 
al., 2016; Sarche & Spicer, 2008). The rates of AUD among Native Americans are high in part due to their 
cultural history of alcohol and tobacco use. Tobacco being used as currency was common practice 
among Native American tribes before European colonization. European colonization brought trade in 
the form of alcohol for tobacco. As European colonization increased, trade and the rate of alcohol 
consumption increased along with it. As a result of this, Native Americans have a very high prevalence of 
alcoholism. 
The pharmacology of alcohol makes recovery from AUD very difficult. The neurotransmitters of 
a person with AUD no longer function normally (Figure 1). Alcohol indirectly binds with the gamma-
aminobutyric acid (GABA) receptors where its action mimics GABA (Figure 2). The GABA receptors are 
found throughout the central nervous system and are major inhibitory neurotransmitters (Olsen & 
DeLorey, 1999). Alcohol inhibits glutamate, interferes with glucose regulation, and causes the 
neurotransmitters dopamine and serotonin to be released (Banerjee, 2014). Dopamine and serotonin 
are responsible for feelings of pleasure, reward seeking, motivation, and several other crucial functions. 
Chronic alcohol consumption can create a physical dependence in the brain that alters brain chemistry 
(Clapp, Bhave, & Hoffman, (2008). (Figure 3). In addition, inhibition of the GABA receptors results in 
reduced anxiety, which prompts the user to seek alcohol when experiencing stress or trauma (Clapp et 
al., 2008). Once the brain has created new pathways, cessation of use becomes incredibly difficult. 
When someone with AUD or a physical dependence on alcohol stops consuming it, they experience 
withdrawal (Banerjee, 2014). Withdrawal is the result of an absence of vital neurotransmitters, 
dopamine, serotonin, and GABA (Clapp et al., 2008). The user’s brain has stopped producing these 
transmitters on its own because alcohol used to provide them (Figure 4). When someone is going 
through alcohol withdraw, they can experience withdrawal symptoms such as, anxiety, depression, 
mood swings, fever, sweating, irritability, nausea, insomnia and delirium (Medlineplus, 2019). These 
symptoms can be life threatening and are the reason that relapse is so common among AUD patients. 
Due to the high prevalence of AUD there are many resources available to help users get into recovery.  
Throughout American history there have been social movements to ban the use of alcohol 
because of its destructive nature. Federal action against alcohol use was taken by the passage of 
prohibition, which was started by the ratification of the 18th amendment of the United States 
Constitution. The 18th amendment made the sale and production of intoxicating liquors illegal (History, 
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2009). The prohibition movement, as it would later be called, was largely led by women, due to the 
destruction alcohol abuse often brings to families (History, 2009). At first prohibition was moderately 
successful in reducing alcohol related arrests and crime (History, 2009). Enforcement proved to be 
difficult though and depended largely on how sympathetic communities were to the new laws (History, 
2009). Illegal alcohol manufacturing, known as bootlegging, and speakeasys (clubs where alcohol was 
illegally sold) began to create an impressive black market for alcohol (History, 2009). Prohibition also 
disproportionally impacted the poor and working class because illegal alcohol was expensive, compared 
to the more well off who could easily pay the increased prices. Prohibition came to an end in 1933 under 
President Roosevelt. He used the legalization of alcohol to spur job creation during the great depression 
and took advantage of the vast cultural desire for legalization. Despite the failure of prohibition, the 
main issue as to why many in the temperance movement wanted to outlaw it was ahead of its time.  
Current research on ACEs brought on by alcoholic parents provide robust scientific support for 
the impact that alcoholism has on children, and families (Dube et al., 2003). There are several 
government resources, such as the Substance Abuse and Mental Health Services Administration 
(SAMHSA) national helpline that is available on their website. Government services such as Medicare 
and Medicaid will cover treatment for AUD among qualified rehab centers. The Affordable Care Act also 
opened many opportunities for treatment for users who opt into it. Additional federal and state 
recovery and prevention organizations and program can be found in the substance use resources listed 
at the end of this resource guide. 
 
 
 
 
Figure 1. An illustration of how healthy neurons function. 
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Source: https://www.drugabuse.gov/news-events/nida-notes/2017/03/impacts-drugs-
neurotransmission 
 
 
Figure 2. How the brain’s glutamate system reacts to alcohol consumption. 
Source: https://pubs.niaaa.nih.gov/publications/arh314/310-339.htm 
 
 
 
Figure 3. Areas of the brain that are effected by alcohol use. 
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 Source: https://pubs.niaaa.nih.gov/publications/arh314/310-339.htm 
 
 
Figure 4. How the brain’s glutamate system functions during alcohol withdrawal.  
Source: https://pubs.niaaa.nih.gov/publications/arh314/310-339.htm 
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Opiates 
The United States has experienced three waves of mass opiate addiction since the 19th 
century (Dark Paradise, 2001). The death toll from overdose caused by any opiate has reached 
almost 400,000 since 1997, and of the 70,200 overdose deaths in 2017 68% involved an opiate 
(Scholl, Seth, Kariisa, Wilson, & Baldwin, 2018; Opioid, 2018). Currently synthetic opioids, like 
fentanyl and illegally manufactured fentanyl analogs are the driving force of overdose deaths 
(Opioid, 2018). The incidence of human immunodeficiency virus (HIV) and other sexually 
transmitted diseases (STDs) in the United States has been rising alongside the opioid epidemic and is 
an urgent public health problem. Recreational drug use has been linked to an increased risk of 
engaging in risky sexual behaviors and acquiring HIV or other STD's (Mitchell & Potenza, 2014). 
Research has found that drug users are more likely to engage in risky behavior, such as impulsivity 
and sensation seeking (Celentano, Latimore, & Mehta, 2008).  
All opioids interact with the endogenous opiate system. Researchers have found that there 
are three types of opioid receptors, mu, kappa, and delta. The mu opioid receptors are the primary 
target of opiates that are commonly abused (Figure 5). When the opioid binds to the mu receptors, 
the brain produces the same biochemical reward response as experienced by normal everyday life 
functions, such as eating or sex (Kosten & George, 2002). Figure 6 illustrates the areas of the brain 
impacted by opiate use. Opioids are highly active in the mesolimbic reward system. The mesolimbic 
system sends dopamine to the nucleus accumbens which causes feelings of pleasure. This chain 
reaction caused by opiate use creates powerful reward pathways in the brain that can reactivate 
and cause opiate craving when stimulated (Kosten & George, 2002). These new pathways in the 
brain persist long after opiate use has stopped, and they can be triggered by intense stress or 
environmental stimuli. The intense feelings of pleasure and wellbeing triggered in the nucleus 
accumbens (NAc) by dopamine from the ventral tegmental area (VTA) creates a reward pathway in 
the prefrontal cortex (PFC) that drives addictive behavior (Figure 6) (Kosten & George, 2002).  
The phenomena of tolerance is when users must take increasing doses of the substance in 
order to achieve the same pharmacological effect (Shenoy & Lui, 2018). Figure 7 illustrates how 
tolerance for opiates builds. Tolerance is dangerous because the negative side effects of the opiates, 
such as respiratory sedation begin to become stronger (Shenoy & Lui, 2018). A user who develops 
tolerance becomes susceptible to developing both physical and psychological dependence (Shenoy 
& Lui, 2018). Physical dependence on opiates will occur from any prolonged use of the drug, even in 
clinical settings. The time it takes to develop physical dependence varies from person to person 
(Shenoy & Lui, 2018). Physical dependence is not the same as opiate addiction. Addictive behaviors, 
such as drug seeking, doctor shopping, or taking more of the drug than needed begin to develop 
when psychological dependence begins. Withdrawal is the major driver of opiate abuse disorder. 
The physical pain and discomfort caused by opiate withdrawal enhances the psychological drive to 
use the drug, this is known as opiate craving (figure 7). Opiate cravings felt during withdrawal are 
powerful influences on behavior and actions the user engages in. Opiate withdrawal has proven to 
be a difficult condition due to the complexity presented by truncated variants in the G-coupled 
opioid receptors, and heterogeneity in receptor interactions (Burma, Kwok, & Trang, 2017). When a 
user begins to experience opiate withdrawal, the nervous system enters a state of hyperexcitability. 
The hyperexcitability of the nervous system during opiate withdrawal causes immense anxiety, 
gastrointestinal distress, restlessness, insomnia, and hyperhidrosis (Burma et al., 2017). 
Noradrenaline which was once suppressed by the opiate use enters a state of enhanced 
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noradrenergic tone, causing withdrawal symptoms (Burma et al., 2017). The drive to alleviate 
symptoms of withdrawal often lead users to seek street opiates, which further amplifies the 
addictive cycle (Burma et al., 2017). There is another type of opiate withdrawal that is lesser known 
but, is beginning to gain the attention of the medical community. Post -acute withdrawal syndrome 
(PAWS) is a phenomenon that occurs after the acute phase withdrawal from a substance (Crane, 
2018). PAWS is most commonly seen in amphetamine, alcohol, benzodiazepine, and opiate abusers 
who had used the drugs for prolonged periods (Crane, 2018). The symptoms of PAWS are not as 
intense as the symptoms during acute withdrawal, but they can last much longer (Crane, 2018). One 
of the major symptoms of PAWS is anhedonia, which is the inability to feel pleasure from typical life 
stimuli. Along with anhedonia PAWS sufferers also experience insomnia, depression, brain fog, and 
difficulty concentrating (Crane, 2018). PAWS is likely a major driver of relapse due to the prolonged 
period the symptoms occur. Users can begin to experience hopelessness because even though they 
have weathered acute withdrawal and stopped their drug abuse, they still feel the effects months 
after they had ceased use (Crane, 2018). When subjected to the symptoms of PAWS for a prolonged 
period, drug use begins to seem like the only way to feel anything again. PAWS will typically subside 
if the user stays sober and practices healthy life habits. The amount of time a user will experience 
PAWS and the likelihood that they will experience it depends on what substance was used and for 
how long (Crane, 2018). Opiate withdrawal also is the main driver in amplifying the risk user’s incur 
during opiate use.  
The effect of opiates on the brain creates intense euphoria but is also sedating. Compared 
to amphetamines both substances cause large amounts of dopamine to be released but 
amphetamines increase the risk of engagement in risky sexual behaviors while the users are “high” 
on the substance. Amphetamines increase energy and lower inhibitions, while opiates sedate and 
relax the user. Opiates also suppress testosterone in both men and women leading to a general 
reduction in libido both while using opiates and when in withdrawal (Le-Merrer, Becker, Befort, & 
Kieffer, 2009). User’s increase their risk of contracting HIV/STDs when they engage in trading sexual 
acts for opiates or engage in sex work for money to support their addiction to opiates. Opiates and 
amphetamines are often used together during circuit parties, which are gatherings where men who 
have sex with men (MSM) engage in social activities and often group drug use/sexual activities. In 
this population it is common to trade sexual favors for drugs and to use drugs to enhance sexual 
experiences (chemsex). These behaviors expose MSM to an increased risk of acquiring HIV/STDs, 
especially when Intravenous (IV) drug use is common (Colfax et al., 2001). Researchers have seen 
that users who injected prescription opioids are more likely to report being HIV-positive and have 
had previous STD diagnoses (Jaeger-Woods, Jaeger, Donenberg, & Wilson, 2013). Women are also at 
an increased risk of being taken advantage of sexually during opiate withdrawal. Women who use 
opioids were subjected to increased rates of sexual violence when compared to women who did not 
use opioids (Mateu-Gelabert, Guarino, Jessell, & Teper, 2015).  
Opioid abuse disorder is particularly difficult to recover from due to the impact that opiates 
have on the user’s brain. Long-term opiate use changes the neuropathways in the user’s brain so 
that even when they have stopped using, they will experience cravings for the substance. Complete 
recovery is possible from long-term opiate use, but recovery can take years. Due to the rise in opiate 
overdose deaths many new treatment tools and modalities are being made available for any user 
who is willing to ask for help. One of the most effective ways to fight opiate addiction is with 
medication assisted treatment. Medication assisted treatment include substituting illicit opioid use 
with prescription opiate use, coupled with behavioral coaching and psychotherapy. Opiate users can 
slowly taper down their prescribed opiates while they learn the deep psychological drivers of their 
addictive behavior. Traumatic childhood experiences, or ACEs are strong predictors of lifetime drug 
abuse and opiate users who have experienced these events need to learn how to cope and heal 
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from them in beneficial ways (Dube et al., 2003). Medication assisted therapy is useful because it 
enables the opiate user to have a stable emotional state while processing these traumatic 
experiences, reducing the likelihood of relapse. Detox programs and 12-step programs are also 
available to help opiate users stop their drug use and learn why they began to use the drugs in an 
unhealthy manner. Several government organizations like the United States department of Health 
and Human Services, National Institute on Drug Abuse, and the National Institute of Health have 
federally funded programs to help people who are suffering from opiate use disorder.  
  
 
 
 
Figure 5. Morphine activates the opioid receptors, reduces the release of y-amniobutyric acid 
(GABA) and causes excess dopamine to be released. 
Source: https://www.the-scientist.com/cover-story/pain-and-progress-38043 
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Figure 6. Opioids stimulate the ventral tegmental area (VTA) releasing dopamine into the 
nucleus accumbens (NAc) which causes intense feelings of pleasure and satisfaction. A feedback loop of 
this reward mechanism then forms between the prefrontal cortex (PFC) and VTA pushing the user to 
pursue this feeling over anything else.  
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2851054/ 
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Figure 7. The mechanism of opioid tolerance and withdrawal.  
Source: https://medium.com/dr-ming-kao/opioid-tolerance-dependence-and-withdrawal-
821ef0ec7dd7 
 
 
 
 
 
 
 
 
 
Rotoloni 15 
   
 
 
 
Amphetamines  
The incidence of amphetamine drug use has increased throughout the United States over the 
last decade (Piper et al., 2018). Amphetamine overdose deaths are the second most common type of 
drug overdose death, behind opiates (NIH). One reason that there has been an increase in amphetamine 
usage over the past decade is because of the class of drugs used for the front-line treatment of ADHD. 
Adderall, Ritalin, Vyvanse, Concerta, Dexedrine, and Focalin are common brand names for 
amphetamine-based prescription ADHD treatment. Methamphetamine is a class of amphetamine that is 
nearly exclusively used for recreational purposes and is the drug of choice for many amphetamine 
addicts. Illicit methamphetamine use is not nearly as prevalent as illicit opioid use and has a strong 
regional component. The 2018 National Drug Early Warning System (NDEWS) reported that admission to 
treatment centers for methamphetamine use west of the Mississippi river (12-29%) was significantly 
higher than admissions east of the Mississippi (<1%), except for the Atlanta metro area which reported 
11% of treatment admissions for methamphetamine use (Artigiani, Hsu, McMandlish, & Wish, 2018). 
Amphetamine use is a particularly salient statistic to note during the opiate epidemic because it is 
frequently the drug of choice for opiate users who are also polysubstance users. Users will combine 
opiates and methamphetamine and inject them (often referred to as speedball or goofball). The result is 
one of the most powerful and deadly forms of illicit drug combinations; many high-profile celebrity 
deaths have been from this combination. 
 Amphetamine drugs are highly addictive due to their pharmacology (figure 8,9). Amphetamines 
primarily act on dopamine receptors, where they increase extracellular dopamine by prolonging 
dopamine receptor signaling in the striatum (Calipari & Ferris, 2013). Dopamine is a vital 
neurotransmitter for proper executive functioning, emotional salience, motivation, and reward 
reinforcement (Calipari & Ferris, 2013). Amphetamines are useful for ADHD treatment because current 
research suggests that a lack of dopamine negatively influences a person’s ability to stay focused, 
motivated, and maintain good executive function. The increase in dopamine is useful for alleviating 
these symptoms, but the impact that these drugs have on reward salience, and motivation can lead to 
dependence and addiction (figure 9). Even when amphetamine drugs are taken as prescribed, they can 
change the brain’s ability to produce dopamine naturally. When this change occurs, a person will 
experience withdrawal effects if they stop taking their medication. Withdrawal can then lead to drug 
seeking behavior and can push a person to use methamphetamine. Methamphetamine and prescription 
amphetamines have the same effect on the brain, but methamphetamine is much stronger in the effects 
than prescription. The effects of methamphetamine are extremely potent that addiction can occur after 
the first use, especially if it is administered intravenously (IV).   
Methamphetamine use is a risk factor for engagement in risky sexual behavior. The incidence of 
methamphetamine use is high in certain populations. Men who have sex with men (MSM), chemsex 
users (enhancement of sex through substances), polysubstance users, and opiate users all have a higher 
incidence of methamphetamine use than the general public (SAMHSA, 2018). Injection drug users who 
shoot methamphetamine are at an increased risk for contracting HIV, or hepatitis B or C (NIH, 2019). 
MSM who participate in methamphetamine injection drug use (IDU) are more likely to engage in risky 
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sexual behaviors, facilitated by methamphetamine use. When methamphetamine is used intravenously 
it causes intense euphoria and decreased inhibition, which lowers the rate of condom use among MSM 
(Bull, Pper, & Rietmeijer, 2002). The NIH has found that methamphetamine users are more likely than 
any other group of substance abusers to contract HIV due to two factors; needle sharing, and the effect 
that methamphetamine has on libido and reward processing (NIH, 2019). Methamphetamine users who 
already had HIV were found to have worse outcomes than non-users and users who were taking highly 
active antiretroviral therapy (HAART) were more likely to develop AIDS (Ellis et al., 2003; Fairbairn et al., 
2011).  
 
 
 
Figure 8. Illustration of a neurotransmitter under the influence of cocaine. Cocaine blocks 
dopamine re-uptake resulting in excess levels of dopamine in the synapse.  
Source: http://universe-review.ca/R10-16-ANS01.htm 
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Figure 9. This illustration shows how the neurotransmitters react to amphetamines causing a 
surge of dopamine and noradrenaline in the synaptic cleft.  
Source: https://forensictoxicology-blog.tumblr.com/post/43936999014/mechanism-of-action 
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Cannabis  
Cannabis or marijuana is the most commonly used illicit substance in the United States. A 2015 
report from the National Survey on Drug use and Health reported that nearly 22.2 million people had 
used marijuana in the last month (SAMSHA, 2018). The monitoring the future survey (MTF) reported 
that 43.6% of 12th graders had reported trying marijuana at least once in their lifetime. The National 
Survey on Drug use and Health showed that 22.1% of people aged 18 through 25 had used marijuana in 
the past month (NIH, 2019). Marijuana’s complex legal status makes it unique when compared to the 
other substances in this resource guide. Marijuana has been federally illegal in the United States since 
the Controlled Substances Act was passed in 1970 by Richard Nixon. Since then the legality of marijuana 
use has repeatedly been a subject of controversy. One of the main reasons for this legal battle is over 
the legitimacy of marijuana use as a medicine. The changing legal status of marijuana has made 
understanding the impact that it has on the brain a pressing research issue. This is especially important 
due to adolescent usage and the impact on engagement in risky behaviors that marijuana use may 
contribute to.  
The active components in marijuana are known as cannabinoids and they interact with the 
bodies endocannabinoid system. The most well-known cannabinoid is delta-9-tetrahydrocannabinol or 
THC. This is a psychoactive cannabinoid that is responsible for the ‘high” feeling that users report after 
consumption of marijuana. The cannabinoid system regulates many important functions like mood, 
appetite, and pain-suppression (figure 10). Marijuana’s ability to inhibit pain is a major driver in the 
effort to allow chronic pain patients access to medical marijuana as an alternative to opiate medication. 
There are two types of cannabinoid receptors cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 
(CB2) (Zou & Kumar, 2018). Receptors CB1 and CB2 are members of the G-protein family. The G-protein 
coupled family of neuroreceptors are abundant through many vital systems in the body and brain (figure 
13). These findings have led scientists to believe that humans evolved the ability to experience 
cannabinoids. There are two main types of canabinoids: Phyto-cannabinoids (cannabinoids that come 
from the plant) THC is an example of this, and endogenous cannabinoids which are formed in the body. 
Examples of endogenous cannabinoids are N-arachidonoylethanolamine or anandamide (AE) or 2-
arachidonoylglycerol (2-AG), purified, and synthetic (NIH, 2018). There is emerging research that 
suggests cannabinoids can have an impact on fertility, but research is mixed. Gorzalka and Dang (2012) 
found that cannabis use heightened male and female sexual proceptivity. They found that as the 
amount of cannabis increased, males began to experience a drop in sexual proceptivity while females 
remained similar with a slight rise (Gorzalka, Hill, & Chang, 2010). Gorzalka and Dang (2012) theorized 
that THC reduces testosterone and luteinizing hormone by binding to the cannabinoid receptors CB1 
and CB2. Mimicking anandamine an endogenous cannabinoid (figure 11). This effect is more present in 
men due to increased levels of testosterone (Gorzalka et al., 2010; Gorzalka & Dang, 2012). It is difficult 
for researchers to further study cannabis due to the changing legal status of the substance. 
The impact that cannabis has on risky sexual behavior is mediated by its legal status. Federally 
cannabis is still listed as a schedule 1 substance and is illegal in the United States. States have voted and 
decided to legalize both medicinal and recreational cannabis use. The distinction between medicinal and 
recreational use differs between states. The distinction between legal and illegal is important to note 
because the legality of a substance can impact the population that uses it. Research has found that the 
impact cannabis has on sexual risk behavior is mediated by the social expectancies the user experiences. 
(Stoner, 2018). Hendershot et al., (2010) investigated this phenomenon and found that among 
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adolescents' strong sexual expectancies that were associated with cannabis use predicted an increase in 
the user’s engagement in risky sexual behavior. The impact that cannabis use has depends also on how 
regularly it is used, if it is used alone or with other substances, and the type of association being 
researched. (Stoner, 2018). Brodbeck, Matter, and Moggi (2006) found that cannabis users aged 16-24 
who reported at least weekly cannabis use were more likely to engage in risky sexual behavior than their 
peers who did not use cannabis. Polysubstance use that included cannabis also was found to impact a 
person’s likelihood of engaging in risky sexual behavior within the pat 12 months (Swartzendruber, 
Sales, Brown, DiClemente, Rose, 2016). Event-Level studies of the impact on cannabis use showed that, 
among adolescents, cannabis use was associated with an increase in risky sexual behaviors, but among 
adults no association was found (Stoner, 2018). Research by Walsh, Fielder, Carey and Carey (2014) 
supports this finding. They found that among the college aged women in their study cannabis use was 
not associated with an increase in risky sexual behavior. The mixed results of these studies show that 
much more research on cannabis’ impact on risky sexual behavior is needed. Currently, researchers 
believe that the impact cannabis has on a person’s risk of engagement in risky sexual behavior is 
dependent on the social expectancies in which cannabis is being used (Stoner, 2018).  
 
 
 
Figure 10. Brain structures in which the endocannabinoid system is active.  
Source: http://headsup.scholastic.com/students/the-science-of-marijuana 
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Figure 11. The similarity of the brain’s natural chemical anandamide and THC from cannabis.  
Source: https://www.drugabuse.gov/publications/research-reports/marijuana/how-does-
marijuana-produce-its-effects 
 
 
 
Figure 13. Illustration of how THC impacts the body's ability to produce neurotransmitters.  
Source: https://www.the-scientist.com/infographics/infographic--how-exposure-to-cannabis-in-
utero-affects-development-65266 
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Trend Graphics of Substance Use in the United 
States 
 
 
Graphic 1: Results from the 2017 NSDUH on illicit drug use.  
Source: https://www.samhsa.gov/data/sites/default/files/nsduh-ppt-09-2018.pdf 
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Graphic 2: Reports of alcohol use disorder given from the 2017 NSDUH 
Source: https://www.samhsa.gov/data/sites/default/files/nsduh-ppt-09-2018.pdf 
Graphic 3: Break down of prescription pain reliever misuse among age categories.  
Source: https://www.samhsa.gov/data/sites/default/files/nsduh-ppt-09-2018.pdf 
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Graphic 4: Precentage of each type of opiate misused the previous year among respondents to the 
NSDUH.  
Source: https://www.samhsa.gov/data/sites/default/files/nsduh-ppt-09-2018.pdf 
 
Graphic 5: Marijuana use in the past year broken down by age group.   
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Source: https://www.samhsa.gov/data/sites/default/files/nsduh-ppt-09-2018.pdf 
  
 
Graphic 6: Prevalence of cannabis use among young adults.   
Source: https://www.samhsa.gov/data/sites/default/files/nsduh-ppt-09-2018.pdf 
 
Graphic 7: Prevalence of methamphetamine use among age groups.  
Source: https://www.samhsa.gov/data/sites/default/files/nsduh-ppt-09-2018.pdf 
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Substance Abuse Resources 
Alcohol CADCA - Anti-Drug Coalitions of America 
NIAAA - National Institute on                                        
Alcohol Abuse and Alcoholism 
AA - Alcoholics Anonymous 
ICCPUD - Interagency Cordination 
Commity on the Prevention of Underage Drinking 
NASADAD - National Association of State                   
Alcohol and Drug Abuse Directors 
NTN - National Treatment Network 
NCADD - National Council on Alcohol and                                  
Drug Dependence  
NPN - National Prevention Network 
NYRF - National Youth Recovery                                               
Foundation 
YPR - Young People in Recovery 
Opiates NIH (HEAL) - National Institute of Health                    
Helping to End Addiction Long-Term 
HHS - Health and Human Services Opioids                             
page 
NA - Narcotics Anonymous 
SMART Recovery - 4 point program to                    
help people overcome addictive behaviors 
NAR-ANON - Support for friends and                         
family of narcotic addicts 
NIDA - National Institute on Drug Abuse                                  
Prevention Tools 
Cannabis NIH - National Institute of Health 
SAMHSA - Substance Abuse and Mental                         
Health Services Administration 
MA - Marijuana Anonymous 
Amphetamines Crystal Meth ANON - Community 
support                          for crystal meth addicts 
ACA - American Addiction Centers 
SAMHSA - Substance Abuse and Mental                          
Health Services Administration 
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